LIVIVO - Search results -

Search results

Result 1 - 10 of total 410

Search options

Article ; Online: Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.

Tamura, Kenji

2019 Volume 49, Issue 11, Page(s) 993–998

Abstract: Both palbociclib and abemaciclib are, oral, highly selective inhibitors of cyclin-dependent kinase 4 and 6, which are proteins involved in cell differentiation and growth. In pivotal phase III trials (PALOMA and MONARCH), they demonstrated a significant ... ...

Abstract	Both palbociclib and abemaciclib are, oral, highly selective inhibitors of cyclin-dependent kinase 4 and 6, which are proteins involved in cell differentiation and growth. In pivotal phase III trials (PALOMA and MONARCH), they demonstrated a significant improvement in median progression-free survival in combination with a nonsteroidal aromatase inhibitor in the first-line, and with a fulvestrant in the second-line in hormone receptor-positive and HER2-negative metastatic breast cancer, respectively. Both palbociclib and abemaciclib were approved, however, ribociclib, the third cyclin-dependent kinase 4/6 inhibitor, has not been approved in Japan. The overall benefits from palbociclib and abemaciclib seem to be equivalent. Subsets analyses suggest that clinical benefits of palbociclib are associated with bone-only disease at baseline, no measurable disease, sensitive to previous endocrine therapy and longer disease-free interval. In contrast, additional benefits from abemaciclib in combination with nonsteroidal aromatase inhibitor or fulvestrant seem to have a relationship with visceral disease, liver metastasis, primary resistant to endocrine therapy, and short treatment-free interval. Abemaciclib induces senescence and apoptosis more than palbociclib does in a time-dependent manner and has potential to produce tumor shrinkage by single use. Neutropenia is more frequent in palbociclib, in contrast, diarrhea, nausea, and liver dysfunction are frequent in abemaciclib. In this review, we provide an overview of the two kinds of cyclin-dependent kinase 4/6 inhibitor, which were already approved in Japan. These differences might be useful information for the proper use in daily practice.
MeSH term(s)	Aminopyridines/therapeutic use ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Aromatase Inhibitors/therapeutic use ; Benzimidazoles/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Female ; Fulvestrant/therapeutic use ; Humans ; Japan ; Piperazines/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Purines/therapeutic use ; Pyridines/therapeutic use
Chemical Substances	Aminopyridines ; Antineoplastic Agents ; Aromatase Inhibitors ; Benzimidazoles ; Piperazines ; Protein Kinase Inhibitors ; Purines ; Pyridines ; Fulvestrant (22X328QOC4) ; abemaciclib (60UAB198HK) ; CDK4 protein, human (EC 2.7.11.22) ; CDK6 protein, human (EC 2.7.11.22) ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22) ; palbociclib (G9ZF61LE7G) ; ribociclib (TK8ERE8P56)
Language	English
Publishing date	2019-10-30
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyz151
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful treatment with nivolumab in a patient with gastric cancer with severe liver failure resulting from multiple liver metastases: A case report.

Ikejiri, Fumiyoshi / Yokomizo, Kanako / Tamura, Kenji

Oncology letters

2024 Volume 27, Issue 6, Page(s) 271

Abstract: Gastric cancer (GC) is a globally prevalent and deadly malignancy often diagnosed at advanced stages, which can be accompanied by liver metastases. Conventional chemotherapy is contraindicated in patients with severe liver failure because several ... ...

Abstract	Gastric cancer (GC) is a globally prevalent and deadly malignancy often diagnosed at advanced stages, which can be accompanied by liver metastases. Conventional chemotherapy is contraindicated in patients with severe liver failure because several chemotherapeutic agents are metabolized by the liver. The present study reports on the successful use of nivolumab in a patient with advanced GC and severe liver failure owing to multiple liver metastases. A 57-year-old man was admitted to Shimane Prefectural Central Hospital (Izumo, Japan) with a 2-week history of appetite loss and jaundice. An upper gastrointestinal endoscopy revealed advanced GC (type IV). Computed tomography examination confirmed wall thickening of the gastric pylorus and the presence of multiple liver metastases. A gastric mucosal biopsy confirmed the diagnosis of HER2-positive gastric adenocarcinoma. S-1 + cisplatin chemotherapy was initiated but had to be halted due to the rapid deterioration in liver function, ultimately leading to acute liver failure. The patient was discharged from the hospital under palliative care. The patient was referred to Shimane University Hospital (Izumo, Japan) for a second consultation. Upon admission, the patient presented with severe liver failure, a Child-Pugh score of 10 (Class C), elevated total bilirubin levels of 13.9 mg/dl (normal range: <1.8 mg/dl) and elevated CEA and CA19-9. Nivolumab treatment was initiated, and notably, there was a substantial reduction in bilirubin levels, an improvement in liver function after a single cycle and a partial response observed in imaging studies. Despite the initial poor prognosis, the patient achieved long-term survival, ultimately succumbing to the illness 2 years and 6 months following the initiation of treatment. The present case underscores the potential of immune checkpoint inhibitors, such as nivolumab, in the treatment of patients with cancer and severe liver failure. It also challenges the conventional constraints of chemotherapy, offering a promising direction for future research in this area.
Language	English
Publishing date	2024-04-18
Publishing country	Greece
Document type	Case Reports
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2024.14404
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [Molecular target therapy].

Tamura, Kenji

Nihon rinsho. Japanese journal of clinical medicine

2016 Volume 74 Suppl 3, Page(s) 226–233

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Cluster Analysis ; Drug Resistance, Neoplasm ; Humans ; Male ; Microarray Analysis ; Molecular Targeted Therapy ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/metabolism
Chemical Substances	Antineoplastic Agents
Language	Japanese
Publishing date	2016-05-20
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390903-7
ISSN	0047-1852
ISSN	0047-1852
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 429: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Romidepsin and tamoxifen cooperatively induce senescence of pancreatic cancer cells through downregulation of FOXM1 expression and induction of reactive oxygen species/lipid peroxidation.

Okuni, Noriko / Honma, Yoshio / Urano, Takeshi / Tamura, Kenji

Molecular biology reports

2022 Volume 49, Issue 5, Page(s) 3519–3529

Abstract: Background: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority.!# ...

Abstract	Background: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. Methods: Pancreatic cancer cell lines were incubated with romidepsin, an inhibitor of histone deacetylase, and tamoxifen, and their effects on cell growth, signaling and gene expression were analyzed. Xenografts of human pancreatic cancer CFPAC1 cells were medicated with romidepsin and tamoxifen to evaluate their effects on tumor growth. Results: The inhibition of the growth of pancreatic cancer cells induced by romidepsin and tamoxifen was effectively reduced by N-acetyl cysteine and α-tocopherol, respectively. The combined treatment greatly induced reactive oxygen species production and mitochondrial lipid peroxidation, and these effects were prevented by N-acetyl cysteine and α-tocopherol. Tamoxifen enhanced romidepsin-induced cell senescence. FOXM1 expression was markedly downregulated in pancreatic cancer cells treated with romidepsin, and tamoxifen further reduced FOXM1 expression in cells treated with romidepsin. Siomycin A, an inhibitor of FOXM1, induced senescence in pancreatic cancer cells. Similar results were obtained in knockdown of FOXM1 expression by siRNA. Conclusion: Since FOXM1 is used as a prognostic marker and therapeutic target for pancreatic cancer, a combination of the clinically available drugs romidepsin and tamoxifen might be considered for the treatment of patients with pancreatic cancer.
MeSH term(s)	Animals ; Cell Line, Tumor ; Cell Proliferation ; Cysteine/metabolism ; Depsipeptides/pharmacology ; Down-Regulation ; Forkhead Box Protein M1/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Lipid Peroxidation ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Reactive Oxygen Species/metabolism ; Tamoxifen/pharmacology ; alpha-Tocopherol/pharmacology ; Pancreatic Neoplasms
Chemical Substances	Depsipeptides ; FOXM1 protein, human ; Forkhead Box Protein M1 ; Reactive Oxygen Species ; Tamoxifen (094ZI81Y45) ; romidepsin (CX3T89XQBK) ; alpha-Tocopherol (H4N855PNZ1) ; Cysteine (K848JZ4886)
Language	English
Publishing date	2022-01-31
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	186544-4
ISSN	1573-4978 ; 0301-4851
ISSN (online)	1573-4978
ISSN	0301-4851
DOI	10.1007/s11033-022-07192-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1140: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Development of cell-cycle checkpoint therapy for solid tumors.

Tamura, Kenji

Japanese journal of clinical oncology

2015 Volume 45, Issue 12, Page(s) 1097–1102

Abstract: Cellular proliferation is tightly controlled by several cell-cycle checkpoint proteins. In cancer, the genes encoding these proteins are often disrupted and cause unrestrained cancer growth. The proteins are over-expressed in many malignancies; thus, ... ...

Abstract	Cellular proliferation is tightly controlled by several cell-cycle checkpoint proteins. In cancer, the genes encoding these proteins are often disrupted and cause unrestrained cancer growth. The proteins are over-expressed in many malignancies; thus, they are potential targets for anti-cancer therapies. These proteins include cyclin-dependent kinase, checkpoint kinase, WEE1 kinase, aurora kinase and polo-like kinase. Cyclin-dependent kinase inhibitors are the most advanced cell-cycle checkpoint therapeutics available. For instance, palbociclib (PD0332991) is a first-in-class, oral, highly selective inhibitor of CDK4/6 and, in combination with letrozole (Phase II; PALOMA-1) or with fulvestrant (Phase III; PALOMA-3), it has significantly prolonged progression-free survival, in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer, in comparison with that observed in patients using letrozole, or fulvestrant alone, respectively. In this review, we provide an overview of the current compounds available for cell-cycle checkpoint protein-directed therapy for solid tumors.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Aromatase Inhibitors/administration & dosage ; Aurora Kinase A/antagonists & inhibitors ; Biomarkers, Tumor/analysis ; Breast Neoplasms/chemistry ; Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Cell Cycle Checkpoints/drug effects ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Proliferation ; Clinical Trials as Topic ; Cyclin-Dependent Kinases/antagonists & inhibitors ; Disease-Free Survival ; Estradiol/administration & dosage ; Estradiol/analogs & derivatives ; Estrogen Receptor Antagonists/administration & dosage ; Female ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Neoplasm Staging ; Nitriles/administration & dosage ; Nuclear Proteins/antagonists & inhibitors ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein-Serine-Threonine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor, ErbB-2/analysis ; Receptors, Estrogen/analysis ; Triazoles/administration & dosage
Chemical Substances	Aromatase Inhibitors ; Biomarkers, Tumor ; Cell Cycle Proteins ; Estrogen Receptor Antagonists ; Nitriles ; Nuclear Proteins ; Protein Kinase Inhibitors ; Receptors, Estrogen ; Triazoles ; fulvestrant (22X328QOC4) ; Estradiol (4TI98Z838E) ; letrozole (7LKK855W8I) ; ERBB2 protein, human (EC 2.7.10.1) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; WEE1 protein, human (EC 2.7.10.2) ; AURKA protein, human (EC 2.7.11.1) ; Aurora Kinase A (EC 2.7.11.1) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1) ; Cyclin-Dependent Kinases (EC 2.7.11.22)
Language	English
Publishing date	2015-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyv131
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Romidepsin and tamoxifen cooperatively induce senescence of pancreatic cancer cells through downregulation of FOXM1 expression and induction of reactive oxygen species/lipid peroxidation

Okuni, Noriko / Honma, Yoshio / Urano, Takeshi / Tamura, Kenji

Molecular biology reports. 2022 May, v. 49, no. 5

2022

Abstract: BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. ... ...

Abstract	BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. METHODS: Pancreatic cancer cell lines were incubated with romidepsin, an inhibitor of histone deacetylase, and tamoxifen, and their effects on cell growth, signaling and gene expression were analyzed. Xenografts of human pancreatic cancer CFPAC1 cells were medicated with romidepsin and tamoxifen to evaluate their effects on tumor growth. RESULTS: The inhibition of the growth of pancreatic cancer cells induced by romidepsin and tamoxifen was effectively reduced by N-acetyl cysteine and α-tocopherol, respectively. The combined treatment greatly induced reactive oxygen species production and mitochondrial lipid peroxidation, and these effects were prevented by N-acetyl cysteine and α-tocopherol. Tamoxifen enhanced romidepsin-induced cell senescence. FOXM1 expression was markedly downregulated in pancreatic cancer cells treated with romidepsin, and tamoxifen further reduced FOXM1 expression in cells treated with romidepsin. Siomycin A, an inhibitor of FOXM1, induced senescence in pancreatic cancer cells. Similar results were obtained in knockdown of FOXM1 expression by siRNA. CONCLUSION: Since FOXM1 is used as a prognostic marker and therapeutic target for pancreatic cancer, a combination of the clinically available drugs romidepsin and tamoxifen might be considered for the treatment of patients with pancreatic cancer.
Keywords	alpha-tocopherol ; carcinoma ; cell growth ; cell senescence ; cysteine ; gene expression ; histone deacetylase ; humans ; lipid peroxidation ; mitochondria ; molecular biology ; neoplasm cells ; pancreatic neoplasms ; reactive oxygen species ; tamoxifen ; xenotransplantation
Language	English
Dates of publication	2022-05
Size	p. 3519-3529.
Publishing place	Springer Netherlands
Document type	Article
ZDB-ID	186544-4
ISSN	1573-4978 ; 0301-4851
ISSN (online)	1573-4978
ISSN	0301-4851
DOI	10.1007/s11033-022-07192-9
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 78/728: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article: A new method for effective use of the ClearPetra ureteral access sheath for a giant ureteral stone.

Nao, Tomoya / Iga, Ryohei / Yoshimura, Rie / Kurano, Yoshitaka / Yamamoto, Shinkuro / Tamura, Kenji

Urology case reports

2023 Volume 51, Page(s) 102599

Abstract: The ClearPetra (Well Lead Medical, Guangzhou, China) has recently entered the market, enabling continuous stone fragmentation and removal while maintaining a continuous perfusion field of view. The efficacy and safety of the ClearPetra renal access ... ...

Abstract	The ClearPetra (Well Lead Medical, Guangzhou, China) has recently entered the market, enabling continuous stone fragmentation and removal while maintaining a continuous perfusion field of view. The efficacy and safety of the ClearPetra renal access sheath (RAS) in percutaneous nephrolithotomy (PCNL) and endoscopic combined intrarenal surgery (ECIRS) have been reported. However, no reports have described the use of the ClearPetra ureteral access sheath (UAS). Here, we report a case of successful ureteroscopic lithotripsy (URSL) for a giant ureteral stone by effectively utilizing the ClearPetra UAS.
Language	English
Publishing date	2023-10-23
Publishing country	United States
Document type	Case Reports
ZDB-ID	2745459-9
ISSN	2214-4420
ISSN	2214-4420
DOI	10.1016/j.eucr.2023.102599
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).

Tamura, Kenji / Mukohara, Toru / Yonemori, Kan / Kawabata, Yumiko / Nicolas, Xavier / Tanaka, Tomoyuki / Iwata, Hiroji

Breast cancer (Tokyo, Japan)

2023 Volume 30, Issue 3, Page(s) 506–517

Abstract: Background: This AMEERA-2 study evaluated the pharmacokinetics, efficacy, and safety of the oral selective estrogen receptor degrader amcenestrant as a monotherapy with dose escalation in Japanese postmenopausal women with advanced estrogen receptor- ... ...

Abstract	Background: This AMEERA-2 study evaluated the pharmacokinetics, efficacy, and safety of the oral selective estrogen receptor degrader amcenestrant as a monotherapy with dose escalation in Japanese postmenopausal women with advanced estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. Methods: In this open-label, nonrandomized, phase I study, patients received amcenestrant 400 mg once daily (QD) (n = 7) and 300 mg twice daily (BID) (n = 3). The incidence of dose-limiting toxicities (DLT), recommended dose, maximum tolerated dose (MTD), pharmacokinetics, efficacy, and safety were assessed. Results: No DLTs were observed and MTD was not reached in the 400 mg QD group. One DLT (grade 3 maculopapular rash) was reported in a patient treated with 300 mg BID. After repeated oral administration of either dosing regimen, steady state reached before day 8, without accumulation. Four out of 5 response-evaluable patients from 400 mg QD group achieved clinical benefit and showed tumor shrinkage. No clinical benefit was reported in the 300 mg BID group. Overall, most patients (8/10) experienced a treatment-related adverse event (TRAE), with skin and subcutaneous tissue disorders most commonly reported (4/10 patients). No ≥ grade 3 TRAE in 400 mg QD group and 1 grade 3 TRAE in 300 mg BID group were reported. Conclusions: Amcenestrant 400 mg QD has a favorable safety profile and has been selected as the recommended Phase II dose for monotherapy for evaluating the safety and efficacy of amcenestrant in a larger, global, randomized clinical trial of patients with metastatic breast cancer. Trial registration: Clinical trial registration NCT03816839.
MeSH term(s)	Female ; Humans ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; East Asian People ; Estrogen Antagonists/administration & dosage ; Estrogen Antagonists/pharmacokinetics ; Estrogen Antagonists/therapeutic use ; Maximum Tolerated Dose ; Receptors, Estrogen/genetics ; Genes, erbB-2/genetics ; Administration, Oral ; Selective Estrogen Receptor Modulators/administration & dosage ; Selective Estrogen Receptor Modulators/pharmacokinetics ; Selective Estrogen Receptor Modulators/therapeutic use
Chemical Substances	Estrogen Antagonists ; Receptors, Estrogen ; Selective Estrogen Receptor Modulators
Language	English
Publishing date	2023-03-29
Publishing country	Japan
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Clinical Trial, Phase I ; Journal Article
ZDB-ID	2052429-8
ISSN	1880-4233 ; 1340-6868
ISSN (online)	1880-4233
ISSN	1340-6868
DOI	10.1007/s12282-023-01443-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5536: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: [DNA repair pathway and molecularly targeted therapy for malignant tumors].

Tamura, Kenji

Rinsho ketsueki] The Japanese journal of clinical hematology

2012 Volume 53, Issue 4, Page(s) 409–416

MeSH term(s)	BRCA1 Protein/genetics ; Benzamides/therapeutic use ; Breast Neoplasms/therapy ; DNA Repair ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Molecular Targeted Therapy ; Mutation ; Neoplasms/genetics ; Neoplasms/therapy ; Ovarian Neoplasms/therapy ; Poly(ADP-ribose) Polymerase Inhibitors ; Poly(ADP-ribose) Polymerases/physiology ; Randomized Controlled Trials as Topic
Chemical Substances	BRCA1 Protein ; BRCA1 protein, human ; Benzamides ; Enzyme Inhibitors ; Poly(ADP-ribose) Polymerase Inhibitors ; iniparib (2ZWI7KHK8F) ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30)
Language	Japanese
Publishing date	2012-04
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Millennium timescale carbon stability in an Andisol: How persistent are organo-metal complexes?

Shimada, Hiroaki / Wagai, Rota / Inoue, Yudzuru / Tamura, Kenji / Asano, Maki

Geoderma. 2022 July 01, v. 417

2022

Abstract: Significant linear correlation between organic carbon (OC) and reactive aluminum and iron (metal) are often observed across a wide range of acidic soils including Andisols, and often explained by the formation of stable organo-metal complexes. However, ... ...

Abstract	Significant linear correlation between organic carbon (OC) and reactive aluminum and iron (metal) are often observed across a wide range of acidic soils including Andisols, and often explained by the formation of stable organo-metal complexes. However, the chemical variation and the long-term stability of the complexes remain unclear. We thus compared two buried A horizons (the burial period of 0.5 and 4.6 kyr, based on tephra chronology) to examine the changes in OC chemistry as well as its association with the metal phases extractable by sodium pyrophosphate (PP) and acid oxalate (OX). Both horizons were subdivided into six layers, and then the layer with the highest OC in each horizon was subjected to particle-size fractionation after maximum dispersion. ¹⁴C ages of the bulk and the size fractions were consistent with the tephra-based burial ages. Younger ¹⁴C age was shown for the organo-mineral fractions of finer sizes in both horizons, in accord with our previous study using a surface Andisol. PP-extractable metal concentration (metalPP) showed a highly significant linear correlation with OC across all the layers and the fractions from both horizons, whereas OX-extractable metal showed the correlation only within the younger buried horizon. Solid-state ¹³C NMR spectroscopy showed a stronger metalPP correlation with alkyl C than with aromatic C especially among the older horizon layers and the ¹⁴C age variation among the size fractions in this horizon was not related to aromaticity. Significant decline in the proportion of O-alkyl C and concurrent increase in that of aromatic C from the younger to older horizon may suggest preferential degradation of O-alkyl C under the buried condition. Over the burial time, however, the correlation between metalPP and aromatic C weakened whereas metalPP-alkyl C correlation increased. These results imply a shift in the dominant organic ligand in the organo-metal complexes. Furthermore, the shift in the distribution of total OC and metalPP from 0.2–2 μm fraction to <0.2 μm fraction suggested a physical weakening of microaggregates where organo-metal complexes likely acted as glue. The observed changes imply reduced OC stability, which may lead to the eventual disappearance of buried A horizons. The current study demonstrated that, while organo-metal complexes appeared persistent based on the OC-metalPP correlation, the changes in the nature of OC-metal association including the partial breakdown of microaggregates took place, in the millennium timescale.
Keywords	Andisols ; aluminum ; biochemical polymorphism ; fractionation ; iron ; ligands ; microaggregates ; nuclear magnetic resonance spectroscopy ; organic carbon ; oxalates ; particle size ; sodium pyrophosphate ; tephra
Language	English
Dates of publication	2022-0701
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	281080-3
ISSN	1872-6259 ; 0016-7061
ISSN (online)	1872-6259
ISSN	0016-7061
DOI	10.1016/j.geoderma.2022.115820
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 2363: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED